Face-to-face interactions, including taking part in community events, may help build trust, reduce health inequities, and increase diversity in clinical trials — a key part to both advancing science and ensuring the most state-of-the-art medicine is accessible to all patients....
Barriers to health care largely due to stigma and discrimination make members of the lesbian, gay, bisexual, transgender, queer and gender-nonconforming community particularly vulnerable to cancer....
Promoting a diverse clinical trial workforce is a key pillar of any effective effort to promote patient population diversity....
Older Black and Latinx adults want a health care system that makes space for addressing individuals’ needs and care preferences and is welcoming and accepting of people’s identities....
Increasing the racial and ethnic diversity of clinical trial participants is a scientific and ethical imperative emerging from differences in disease causality, presentation, and progression; in access to health care; and in drug safety and effectiveness across diverse populations....
Patient-driven consent-management tools and granular data segmentation need to be balanced for health equity, patient privacy and interoperability....
COVID-19 safety precautions have been rescinded as many try to to return to a sense of pre-pandemic normalcy. But the reality of disabled and immunocompromised people remains forgotten, causing them to feel left behind and further pushed out of society, disability advocates say....
The clinical trial industry must be proactive and transparent in its communications with underserved communities with less access to healthcare resources and a wariness about participating in medical research....
We need to widen the data net and do a better job of analyzing those data to identify clinical trials participants from previously ignored patient populations....
Clinical trial diversity is garnering more attention from lawmakers as they seek to resolve a longstanding deficiency amid a larger national focus on health equity....
